RxDoctor Payments Data

Son Nguyen, MD

Internal Medicine · Seattle, WANPI 1508927716

Payments from drug & device makers

$2,697in general payments, 2019–2025

Across 136 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$391
  • Gilead$354
  • GSK$321
  • AstraZeneca$308
  • Johnson & Johnson$269
  • Boehringer Ingelheim$264
  • plus $790 from 7 others

What the payments were for

  • Food & beverage$2,64498%
  • Education$522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,697 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$21,792
Medicare patients
36
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol320$373,247
JardianceEmpagliflozin76$104,195
Tresiba Flextouch U-200Insulin Degludec25$66,359
JanumetSitagliptin Phos/Metformin Hcl68$66,000
VemlidyTenofovir Alafenamide35$52,161
KerendiaFinerenone56$47,190
XareltoRivaroxaban40$44,049
LinzessLinaclotide30$41,135
EliquisApixaban29$31,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$30,423
JanuviaSitagliptin Phosphate19$27,485
RybelsusSemaglutide12$22,287
SymbicortBudesonide/Formoterol Fumarate53$19,289
Calcitonin-SalmonCalcitonin,salmon,synthetic94$10,523
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide874$8,368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$308$392,536373 claims
Boehringer IngelheimJardiance, Tradjenta$264$110,19088 claims
MerckJanumet, Januvia$83$93,48587 claims
GileadVemlidy$354$52,16135 claims
BayerKerendia$245$47,19056 claims
Johnson & JohnsonXarelto$269$44,04940 claims
AbbVieLinzess$101$41,13530 claims
GSKTrelegy Ellipta$321$30,42316 claims
Novo NordiskRybelsus$391$22,28712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →